Clinical Trial Update: Evaluating the Efficacy and Safety of Different Human Thrombopoietin (rhTPO) Regimens in the Treatment of Patients With Primary Immune Thrombocytopenia (ITP) [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating different rhTPO regimens for efficacy and safety in patients with primary immune thrombocytopenia (ITP) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• rhTPO (recombinant human thrombopoietin) (recombinant human thrombopoietin)

Snippet

Sponsor: Shenyang Sunshine Pharmaceutical Co., LTD. | Conditions: ITP | Phase 4 | Status: COMPLETED